BR0207251A - Composição em suspensão - Google Patents

Composição em suspensão

Info

Publication number
BR0207251A
BR0207251A BR0207251-3A BR0207251A BR0207251A BR 0207251 A BR0207251 A BR 0207251A BR 0207251 A BR0207251 A BR 0207251A BR 0207251 A BR0207251 A BR 0207251A
Authority
BR
Brazil
Prior art keywords
suspension composition
composition
tocopherol
derivative
disclosed
Prior art date
Application number
BR0207251-3A
Other languages
English (en)
Inventor
Yong-Sik Kim
Je Phil Ryoo
Mi-Suk Choi
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of BR0207251A publication Critical patent/BR0207251A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçãO EM SUSPENSãO". é exposta uma composição em suspensão para a liberação sustentada contendo cloridreto de ceftiofur, tocoferol ou um derivado dos mesmos, e um óleo biocompatível.
BR0207251-3A 2001-02-19 2002-02-04 Composição em suspensão BR0207251A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2001-0008164A KR100423895B1 (ko) 2001-02-19 2001-02-19 셉티오퍼 하이드로클로라이드의 현탁제 조성물
PCT/KR2002/000161 WO2002066006A1 (en) 2001-02-19 2002-02-04 Sustained-release suspension of ceftiofur hydrochloride

Publications (1)

Publication Number Publication Date
BR0207251A true BR0207251A (pt) 2004-02-10

Family

ID=19705921

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0207251-3A BR0207251A (pt) 2001-02-19 2002-02-04 Composição em suspensão

Country Status (10)

Country Link
US (1) US20040067926A1 (pt)
EP (1) EP1367996A4 (pt)
KR (1) KR100423895B1 (pt)
CN (1) CN1536987A (pt)
AU (1) AU2002232263B8 (pt)
BR (1) BR0207251A (pt)
MX (1) MXPA03007252A (pt)
NZ (1) NZ527323A (pt)
WO (1) WO2002066006A1 (pt)
ZA (1) ZA200306391B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040015622A (ko) * 2002-08-13 2004-02-19 대한뉴팜(주) 세프티오푸르나트륨을 활성성분으로 함유하는 현탁주사액조성물
KR100756190B1 (ko) * 2004-04-16 2007-09-05 주식회사 만도 자동차 브레이크 부스터의 랜싱장치
CN101406447B (zh) * 2007-10-12 2010-08-25 河南农业大学 复方头孢噻呋油混悬注射液制备工艺
WO2009145619A1 (en) * 2008-04-17 2009-12-03 Prosensa Holding Bv Antibiotic composition
AU2009316708B2 (en) * 2008-11-19 2014-07-17 Boehringer Ingelheim Animal Health USA Inc. Formulations comprising ceftiofur and ketoprofen or ceftiofur and benzyl alcohol
CN102973583B (zh) * 2012-11-22 2014-11-12 青岛绿曼生物工程有限公司 治疗家禽腹泻的复方硫酸庆大霉素组合物及其制备方法
CN104546704B (zh) * 2013-12-10 2017-04-05 中国农业科学院饲料研究所 一种奶牛干乳期用盐酸头孢噻呋乳房注入剂及其制备方法
WO2017119928A1 (en) 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long acting injectable formulations
CN106176598B (zh) * 2016-08-30 2019-01-08 林州中农颖泰生物肽有限公司 一种盐酸头孢噻呋混悬注射液及其制备方法
CN109568255A (zh) * 2018-12-19 2019-04-05 南京农业大学 含头孢噻呋和美洛昔康的复方长效注射液及其制备方法
CN113209015A (zh) * 2020-01-21 2021-08-06 江西邦诚动物药业有限公司 长效盐酸头孢噻呋混悬注射液及其制备工艺

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612194A (en) * 1984-02-15 1986-09-16 Roshdy Ismail Anti-rheumatic agents and their use
US4902683A (en) * 1984-10-25 1990-02-20 The Upjohn Company Crystalline cephalosporin hydrohalide salts
IT1181672B (it) * 1984-10-25 1987-09-30 Upjohn Co Cefalosporina alogenidrato cristallino
ATE73333T1 (de) * 1987-07-29 1992-03-15 Upjohn Co Kontrollierte freisetzung von antibiotika-salzen aus einem implantat.
US4877782A (en) * 1988-02-16 1989-10-31 The Upjohn Company Zinc ceftiofur complexes
AU614465B2 (en) * 1989-04-05 1991-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
JPH02286625A (ja) * 1989-04-27 1990-11-26 Dainippon Pharmaceut Co Ltd 注射用持続性製剤
AU653325B2 (en) * 1990-02-12 1994-09-29 Lucky Limited A composition durably releasing bioactive polypeptides
KR940011013A (ko) * 1992-11-27 1994-06-20 최근선 서방성 소마트로핀 제제의 제조방법
SK283674B6 (sk) * 1993-03-12 2003-11-04 Pharmacia & Upjohn Company Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje
US5786387A (en) * 1994-03-23 1998-07-28 Meiji Seika Kabushiki Kaisha Lipid double-chain derivative containing polyoxyethylene
US5736151A (en) * 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
US6074657A (en) * 1997-03-20 2000-06-13 Pharmacia & Upjohn Company Administration of an injectable antibiotic in the ear of an animal

Also Published As

Publication number Publication date
AU2002232263B8 (en) 2006-11-23
KR100423895B1 (ko) 2004-03-24
US20040067926A1 (en) 2004-04-08
EP1367996A4 (en) 2005-04-13
AU2002232263B2 (en) 2006-05-25
ZA200306391B (en) 2004-08-02
KR20020067814A (ko) 2002-08-24
NZ527323A (en) 2006-10-27
EP1367996A1 (en) 2003-12-10
CN1536987A (zh) 2004-10-13
MXPA03007252A (es) 2003-12-04
WO2002066006A1 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
AU2002353971A1 (en) Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
AP1718A (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors
BR9908004A (pt) Composto, composição e método para prevençãoou supressão de uma infecção viral
DK1114032T3 (da) 4-aminosubstituerede-2-substituerede-1,2,3,4-tetrahydroquinoliner som CETB-inhibitorer
BR0207251A (pt) Composição em suspensão
ATE376996T1 (de) Antibakterielle mittel
MA27230A1 (fr) Derives d'aminoindazoles comme inhibiteurs de proteines-kinase
IL192937A0 (en) Pharmaceutical compositions containing beta-lapachone or derivatives or analogs thereof, and methods of using same
ATE307865T1 (de) Grundölzusammensetzung
DK1401501T3 (da) Orale farmaceutiske sammensætninger med modificeret frigivelse af den aktive ingrediens
BR9813228A (pt) Formulação de 2-metil-tieno-benzodiazepina
FR2799458B1 (fr) Compositions de cimentation et application de ces compositions pour la cimentation des puits petroliers ou analogues
PT1117401E (pt) Composicoes antibioticas para o tratamento do olho
BR0011244A (pt) Composições contendo creatina em suspensão
HK1030218A1 (en) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same.
IS2212B (is) 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyrarramide
EP1426370A4 (en) PROPANOLAMINE DERIVATIVE WITH 1,4-BENZODIOXANE CORE
DE60205547D1 (de) Hydraulisches Antischwingungslager
DK0810220T3 (da) Arylacrylamidderivater som 5-HT1-agonister eller -antagonister
PT102832A (pt) Equipamento de suspensao
PT1119359E (pt) Formulacao de 2-metil-tieno-benzodiazepina
BR9901058A (pt) N-cail e n-aroil aralquil amidas.
DE60204518D1 (de) Hydraulisches Antischwingungslager
DE69926887D1 (de) Zusätze und ölzusammensetzungen
SE9904404L (sv) Ny komposition

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CTCBIO INC. (KR)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA.INT.CI.A61K 9/10, A61P 31/04

Ipc: A61K 9/10 (2011.01), A61P 31/04 (2011.01)

B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.